Why does UltraGreen IPO Singapore matter for DBS investors?

It signals live demand for profitable medtechs on SGX. DBS was a joint bookrunner, so more listings can lift fee income across underwriting, advisory, and trading support. A healthier pipeline often improves market depth and wealth flows, which also helps banks’ treasury and wealth units. It is a clean, cyclical tailwind to watch.

Is D05.SI attractive on valuation today?

DBS trades at 15.23x earnings and 2.47x book, with a 4.79% dividend yield. ROE is 16.57%, supporting a premium to peers. Near‑term momentum is strong, though technicals are near overbought. For long‑term buyers, scaling entries on pullbacks toward the 50‑day average can balance value and trend.

What could sustain the SGX IPO pipeline after UltraGreen?

More high‑quality issuers in healthcare, energy transition, and consumer tech could follow. Clear profitability, sensible pricing, and post‑listing liquidity matter. If deals price well and trade up, confidence builds, encouraging more supply. That cycle supports DBS underwriting, trading revenues, and broader market participation from funds and family offices.

What are the key risks to the DBS fee outlook?

A risk‑off backdrop, weaker earnings from new issuers, or delayed approvals can slow listings. If pricing windows close, underwriting and advisory fees ease. Macro shocks, higher credit costs, or rate swings can also pressure bank shares. Active risk management and diversified revenue lines can soften the impact.

Global Market Insights

D05.SI Stock Today: January 29 UltraGreen IPO Revives SGX Deal Flow

ByDanny Kontos January 29, 2026January 29, 2026

UltraGreen IPO Singapore is back in focus as the US$400 million December float, the biggest non‑REIT listing in eight years, stirs SGX deal flow. For investors in D05.SI, the link is direct: DBS was a joint bookrunner, and a sustained pipeline can lift fee income. The stock trades near S$59.79, up 0.88%, with volume above average. Rising medtech listing demand, paired with DBS underwriting strength, sets a constructive backdrop for Singapore’s primary market and bank earnings sensitivity to deals.